Figure 1

Effects of oxaliplatin and CD95 activation on cell migration and adhesion in oxaliplatin-resistant cells. A) To determine the effects of oxaliplatin or CD95 triggering on cell migration different sensitive (HT29 and HCT116 p53^-/-) and resistant (RHT29 and RHCT116 p53^-/-) cell lines were treated with oxaliplatin (10 μM for the HT29 and RHT29 and 5 μM for the HCT116 p53^-/- and RHTC116 p53^-/-) or/and the CD95 agonistic antibody CH11 (150 ng/ml) for 24 hours, and their migratory ability was assessed in transwell assays. The contribution of CD95 activation to oxaliplatin-induced cell migration was determined by inhibiting CD95 expression with siRNA. B) The effects of oxaliplatin or CD95 triggering on the adhesion ability of the different cell lines or the contribution of CD95 activation to oxaliplatin-induced cell adhesion were determined under the same experimental conditions on fibronectin coated plates. The experiments were performed in triplicate and results represent the mean ± SEM. Values that are significantly different from control group by ANOVA's analysis are indicated by *p < 0.05, **p < 0.01, and those different from the oxaliplatin-treated group are indicated by •p < 0.05. OXA: oxaliplatin, FBS: Fetal bovine serum.